Multiple Sclerosis research hub

Effects of CLADribine tablets on the Immune Synapse, in Relapsing Multiple Sclerosis (RMS) patients_CLADIS.

This study looks at how a medicine called MAVENCLAD affects the body's defence system in people with a type of multiple sclerosis. Researchers want to see if it changes how immune cells communicate and how this affects their MS over one year.

An autologous and antigen-specific cell-based therapy of vitamin D3-treated and myelin-derived peptide loaded tolerogenic dendritic cells in subjects with progressive forms of multiple sclerosis: a phase IIa, open-label, self-controlled, multi-center clinical trial.

This study is testing a new cell therapy called tolDC for people with progressive forms of Multiple Sclerosis (MS). It aims to see if tolDC can slow down how MS affects your body and if it's safe to use.

A Randomized Open Label Trial Exploring the Soluble and Imaging Biomarker Dynamic Responses to Tolebrutinib Compared to Rituximab Treatment in Patients with Multiple Sclerosis (MS)

This study compares two treatments, Tolebrutinib and Rituximab, for Multiple Sclerosis (MS). Researchers are looking at how these medicines affect certain markers in the body, especially in the fluid around the brain and spine, to see which one works best at protecting nerves.

Assessing NHS ImplemeNTation of an onlinE Resilience Training Acceptance and Commitment Therapy (ACT) Programme to Prevent Job Loss in Multiple Sclerosis

This study is testing an online programme called 'READY for MS' to help people with Multiple Sclerosis (MS) keep their jobs. It aims to see if training NHS staff to deliver this programme can help people with MS stay in work for longer.

A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)

This study is testing a higher dose of a medicine called ocrelizumab for adults with a type of multiple sclerosis (MS) called relapsing MS. It compares the new dose to the standard dose to see if it's more effective and safe.

A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)

This study looks at a new, higher dose of ocrelizumab for people with primary progressive multiple sclerosis (PPMS). Researchers want to see if this dose is safe and works better than the current approved dose to slow down the disease.

OCTive: A New Horizon in MS Digital Solution

This study is testing new digital tools to better understand how Multiple Sclerosis (MS) changes over time. It uses apps to check movement and special eye scans, hoping to offer a clearer, more personal view of MS progression for people in the UK.

Comparing Transanal Irrigation With Navina Smart vs. Standard Bowel Care in Patients With Multiple Sclerosis

This study compares two ways to manage bowel problems caused by multiple sclerosis (MS): a new device called Navina Smart and standard care. It’s for adults with MS who haven't tried this specific device before, to see if the new method works better.

Concentration of Ofatumumab in the Breast Milk of Lactating Women With Relapsing Forms of Multiple Sclerosis

This study looks at how much ofatumumab, a medicine for multiple sclerosis, gets into breast milk. We want to see if it's safe for mothers with MS who are breastfeeding to take this medication. It involves collecting milk and blood samples from new mums.

A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis

This study looks at the long-term safety and effectiveness of a medicine called ocrelizumab for people with Multiple Sclerosis (MS). It's for people already taking part in other ocrelizumab studies, to see how the treatment works over a longer time.

Optimising Access to Vocational Rehabilitation for People With Multiple Sclerosis

This study looks at how MS charities can help people with MS stay in their jobs. It tests a special support program to see if it's practical and helpful, especially for those who might not get help elsewhere.

Multiple Sclerosis: FutureMS-2 - an Observational Cohort and Scottish Precision Medicine Study

FutureMS-2 is a study following people with MS in Scotland to understand how the condition changes over many years. It builds on an earlier study, aiming to answer important questions about how MS affects individuals and how best to manage it.

A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ≤55 Years

This study is looking into a new medicine called mRNA-1195 to see if it can help stop relapses in people with Multiple Sclerosis (MS). It compares mRNA-1195 with a dummy treatment (placebo) to check its safety and how the body reacts to it.

Validation of the 18 kiloDalton Translocator Protein (TSPO) as a Novel Neuroimmunodulatory Target

This study looks at new ways to treat multiple sclerosis (MS) by targeting a protein called TSPO. We're testing two drugs, XBD173 and Etifoxine, to see if they can reduce harmful immune activity in people with secondary progressive MS and in healthy volunteers.

Hesperidin RCT in MS

This study looks into whether a natural plant extract called hesperidin, found in citrus fruits, can help people with Multiple Sclerosis (MS) feel less tired and improve their thinking. Half the participants will get hesperidin, and the other half a dummy pill.

Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis

This study looks at how safe and effective two medicines, fingolimod and interferon beta-1a, are for young people aged 10-17 with multiple sclerosis (MS). It compares them to see which works best and is safest.

Individualised Cryoneurolysis to Treat Pain in the Context of Spasticity in the Upper and Lower Extremities

This study compares two treatments, cryoneurolysis (freezing nerves) and botulinum toxin (Botox), for pain caused by spasticity. It aims to see which treatment works best for people with conditions like stroke, MS, or spinal cord injury, by looking at pain, movement, and daily activities.

Covid-19 Vaccine Immune Response in Multiple Sclerosis

This study looks at how well COVID-19 vaccines work in people with Multiple Sclerosis (MS). It compares their immune response to people without MS, by checking how many protective antibodies they make after vaccination.

A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2)

This study is looking at a new drug called CC-97540 for people with certain types of Multiple Sclerosis (MS) or a muscle weakness condition called Myasthenia Gravis (MG). We want to see if it's safe, how well people can handle it, and if it helps their condition.

Longitudinal Assessment of Iron Rims in MS Lesions

This study looks at how 'iron rims' around MS lesions on brain scans might affect the disease. We're also checking blood samples for genetic links. Some participants might get another special MRI scan to see how these iron rims change over time.

Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis

This study is looking at a new medicine called frexalimab for people aged 18-55 with certain types of Multiple Sclerosis (MS). It compares frexalimab to an existing MS medicine, teriflunomide, to see how well it stops MS relapses and if it's safe.

Metabolic Imaging of Neurological Disease

This study uses new scanning technology to look at how the brain uses sugar in people with Multiple Sclerosis (MS) or after a stroke, compared to healthy volunteers. It aims to understand brain changes and takes place at the University of Oxford.

Tenofovir Alafenamide Fumarate and Epstein-Barr virus activity in people with MS – The TAF-MS study

Safety Study to Compare the Gastrointestinal Tolerability of Oral Tegomil Fumarate and Dimethyl Fumarate (Tecfidera®) in Healthy Volunteers.

A Phase 2 double blind, randomized, placebo controlled study evaluating the effect of SAR443820 on serum neurofilament levels in participants with multiple sclerosis, followed by an open-label long-term extension period

Clemastine fumarate as remyelinating treatment in internuclear ophthalmoparesis and multiple sclerosis (RESTORE)

A controlled phase II clinical trial evaluating the safety and efficacy of myelin peptide-loaded tolDC as treatment for Multiple Sclerosis

Dendritic cells therapy combined with immunomodulatory treatment in multiple sclerosis

DESIRE MS: A prospective randomized non-inferiority trial comparing anti-CD20 maintenance versus De-Escalation Strategy In Relapsing-Remitting Multiple Sclerosis

A Phase 1, Single-Center, Open-Label, Fixed-Sequence, 2-Part Study to Assess the Pharmacokinetics of IMU-838 Administered Alone and in Combination with Multiple Doses of Gemfibrozil as CYP2C8 Inhibitor, or Rifampicin as CYP2C8 Inducer, in Healthy Subjects

TARGET-EBV in MS: A prospective randomized controlled parallel group phase 2b double blinded study to investigate if targeting Epstein Barr Virus with Tenofovir Alafenamide Fumarate compared to placebo as add-on treatment to anti-CD20 therapy reduces neuronal damage in multiple sclerosis

A study investigating the effect of curcumin on the absorption and elimination of IMU 838, a new compound that may potentially be used in the treatment of multiple sclerosis, and the effect of IMU 838 on the absorption and elimination of rosuvastatin.

Prospective, randomized, double-blind, placebo-controlled, single-center comparative trial evaluating oral hydroxychloroquine 200 mg BID for reducing microglial activation in the brain of patients with progressive multiple sclerosis (MS)

Improving Cognitive Recovery in Multiple Sclerosis

This study looks at a new program, CIRCuiTS-MS, to help people with Multiple Sclerosis (MS) improve their thinking skills. It will check if the program is practical and helpful, paving the way for a larger trial to improve daily life for those with MS.

Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis

This study is testing a new drug called frexalimab for people with a type of multiple sclerosis (MS) called non-relapsing secondary progressive MS (nrSPMS). Researchers want to see if it can slow down MS progression and if it's safe. It's compared to a dummy drug (placebo).

Digital App for Speech & Health Monitoring

This study is using a smartphone app to record and analyse speech from people with conditions like dementia, MND, MS, and Parkinson's. The goal is to see if speech changes can help diagnose and monitor these conditions, comparing them to healthy individuals, using simple digital technology.

An Open-label Study of AZD0120 in Adults With Multiple Sclerosis

This study is testing a new treatment called AZD0120 for adults with multiple sclerosis (MS). It's a first step to see how safe the treatment is and if people can tolerate it well. We're looking at different types of MS to find the right dose.

Natalizumab for the Treatment of People With Inflammatory Demyelination Suggestive of Multiple Sclerosis, or Definite Multiple Sclerosis, at First Presentation (AttackMS)

This study investigates whether starting a highly effective MS treatment, Natalizumab (Tyruko®), very soon after someone first shows symptoms can help repair nerve damage. It focuses on people with early signs of MS or a definite diagnosis.

A Study of LY3541860 in Adult Participants With Relapsing Multiple Sclerosis

This study is testing a new drug, LY3541860, for adults with relapsing multiple sclerosis (MS). We want to see if it's safe and helps reduce MS flare-ups. The study will last about 9 months, with a 6-month follow-up.

A Novel Wearable Digital Biomarker for Detecting Changes in Multiple Sclerosis (MS) Condition

Artificial Intelligence-Assisted Magnetic Resonance Imaging for Quality, Efficiency and Equity in the National Health Service (NHS) Care of Multiple Sclerosis